Physician profile
Christopher E Cossette
NPI 1629483268
$2,525.76
in general payments reported to CMS, 2019-2025
14 companies · $465 in 2025
The $465 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $219 · 2021: $240 · 2022: $444 · 2023: $438 · 2024: $408 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $492.35 | 2019-2025 | Precision7, Dailies, Total30 |
| Johnson & Johnson Vision Care, INC. | $426.95 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $400.53 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $254.23 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $187.03 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $155.42 | 2019-2022 | |
| Shire North American Group INC | $136.48 | 2019 | |
| Biotissue Holdings INC. | $126.89 | 2023 | |
| Lkc Technologies, INC. | $113.75 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.67 | 2019-2021 | |
| The Cameron-Ehlen Group, INC. | $77.07 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.62 | 2021 | |
| Glaukos Corporation | $18.28 | 2022 | |
| Abbvie INC. | $15.49 | 2023 | Lumigan, Alphagan P, Vuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cossette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.